REG - Integrated Diag Hdgs - Notice of Results

Integrated Diagnostics HoldingsAnnouncement

30/08/2023 10:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230830:nRSd8081Ka&default-theme=true

RNS Number : 8081K  Integrated Diagnostics Holdings PLC  30 August 2023

Integrated Diagnostics Holdings Plc Notice of Results

 

30 August 2023

 

(London) Integrated Diagnostics Holdings ("IDH," "the Group," or "the
Company"), a leading provider of diagnostic services with operations in Egypt,
Jordan, Nigeria, Sudan, and soon launching in Saudi Arabia, will publish its
reviewed financial statements for the six-month period ended 30 June 2023 on
Thursday, 31 August 2023 at 7am (UK).

 

An analyst and investor call will be hosted at 1pm (UK) | 3pm (Egypt) on
Monday, 4 September 2023. You can register for the call by clicking on this
link
(https://efghermesevents.webex.com/webappng/sites/efghermesevents/meeting/register/bef52f90ea164d3aa8f30b8f46b13ea8?ticket=4832534b000000065528d8d1c45993a3097d0a50e0da964aa1011a4220048c46bc0c776a87b8fb5a×tamp=1693296951596&RGID=rcbd126d3793dccd452c9fb551c0196a6)
.

 

For more information about the event, please contact: amoataz@EFG-HERMES.com
(mailto:amoataz@EFG-HERMES.com)

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa
offering a broad range of pathology and radiology tests to patients in Egypt,
Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg
Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al
Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of over 2,000
diagnostics tests. From its base of 552 branches as of 31 December 2022, IDH
served over 8.7 million patients and performs more than 32.7 million tests in
2022. IDH will continue to add laboratories through a Hub, Spoke and Spike
business model that provides a scalable platform for efficient expansion.
Beyond organic growth, the Group's expansion plans include acquisitions in new
Middle Eastern, African, and East Asian markets where its model is well-suited
to capitalise on similar healthcare and consumer trends and capture a
significant share of fragmented markets. IDH has been a Jersey-registered
entity with a Standard Listing on the Main Market of the London Stock Exchange
(ticker: IDHC) since May 2015 with a secondary listing on the EGX since May
2021 (ticker: IDHC.CA). Learn more at idhcorp.com (http://idhcorp.com) .

 

The person responsible for arranging the release of this announcement is Nancy
Fahmy, Investor Relations Director at IDH.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com
(mailto:nancy.fahmy@idhcorp.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGFRRGKGFZG